LCK: A Protein Implicated in Cancer and Diagnosis (G3932)

Target Name: LCK

NCBI ID: G3932

Content of Review Report on LCK Target / Biomarker

LCK

LCK: A Protein Implicated in Cancer and Diagnosis

LCK, or lymph node metastasis protein, is a protein that is expressed in various tissues throughout the body, including lymphoid organs such as the lymph nodes, spleen, and bone marrow. It is a member of the T-cell receptor (TCR) family, which is a critical receptor for the recognition of foreign antigens by T-cells.

The discovery and characterization of LCK has important implications for the study of cancer biology, as well as the development of new diagnostic tests and therapies. LCK has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer, and has been used as a biomarker for these cancers.

In addition to its use as a cancer biomarker, LCK has also been identified as a potential drug target. Several studies have shown that LCK can interact with various drug molecules, including small molecules, antibodies, and signaling proteins. These interactions may lead to the inhibition of LCK-mediated signaling pathways, which could be useful for the development of new treatments for cancer.

One of the most promising strategies for the targeting of LCK is the use of small molecules that can inhibit the activity of LCK. These small molecules can be designed to interact with specificLCK domains, such as the catalytic domain or the N-terminus, and have been shown to be effective in cell experiments.

Another approach to targeting LCK is the use of antibodies that can selectively bind to LCK. These antibodies can be used to visualize LCK in cells and tissues and can also be used to block the activity of LCK in cell experiments. The use of antibodies to target LCK has been shown to be effective in preclinical studies for the treatment of various types of cancer.

In addition to these therapeutic approaches, LCK has also been used as a diagnostic biomarker for cancer. Several studies have shown that LCK can be used as a protein biomarker for various types of cancer, including breast, ovarian, and prostate cancer. These biomarkers can be used to diagnose the disease at an early stage, when treatment is most effective.

The use of LCK as a diagnostic biomarker has the potential to revolutionize the field of cancer medicine. By using LCK as a diagnostic marker, doctors can diagnose cancer at an early stage and begin targeted treatments that are more effective and less invasive.

In conclusion, LCK is a protein that has important implications for the study of cancer biology and the development of new diagnostic tests and therapies. Its use as a cancer biomarker and its potential as a drug target make it an attractive target for researchers and clinicians alike . Further studies are needed to fully understand the role of LCK in cancer biology and its potential as a diagnostic biomarker.

Protein Name: LCK Proto-oncogene, Src Family Tyrosine Kinase

Functions: Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells. Plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. Constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, thereby recruiting the associated LCK protein to the vicinity of the TCR/CD3 complex. LCK then phosphorylates tyrosine residues within the immunoreceptor tyrosine-based activation motifs (ITAM) of the cytoplasmic tails of the TCR-gamma chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. Once stimulated, the TCR recruits the tyrosine kinase ZAP70, that becomes phosphorylated and activated by LCK. Following this, a large number of signaling molecules are recruited, ultimately leading to lymphokine production. LCK also contributes to signaling by other receptor molecules. Associates directly with the cytoplasmic tail of CD2, which leads to hyperphosphorylation and activation of LCK. Also plays a role in the IL2 receptor-linked signaling pathway that controls the T-cell proliferative response. Binding of IL2 to its receptor results in increased activity of LCK. Is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature alpha beta TCR. Phosphorylates other substrates including RUNX3, PTK2B/PYK2, the microtubule-associated protein MAPT, RHOH or TYROBP. Interacts with FYB2 (PubMed:27335501)

The "LCK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets